LabCorp — Patient Report

Specimen ID: 179-042-0879-0
Control ID: ACD29064360

Phone: [redacted] Rte: 00

726

)1-2575

Specimen Det
Date collected:
Date received:
Date entered:
Date reported:

Physician Details
Ordering:
Referring:
ID: [redacted]
NPI:

Ordered Items
SARS-CoV-2, NAA

TESTS	RESULT	FLAG	UNITS	REFERENCE INTERVAL	LAB
SARS-CoV-2, NAA	Not Detected			Not Detected	01

Testing was performed using the cobas(R) SARS-CoV-2 test.
This test was developed and its performance characteristics determined by LabCorp Laboratories. This test has not been FDA cleared or approved. This test has been authorized by FDA under an Emergency Use Authorization (EUA). This test is only authorized for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostic tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.
When diagnostic testing is negative, the possibility of a false negative result should be considered in the context of a patient's recent exposures and the presence of clinical signs and symptoms consistent with COVID-19. An individual without symptoms of COVID-19 and who is not shedding SARS-CoV-2 virus would expect to have a negative (not detected) result in this assay.

01 RN LabCorp Raritan
69 First Avenue, Raritan, NJ 08869-1800
Dir: [redacted], MD

For inquiries, the physician may contact **Branch: 800-631-5250 Lab: 800-631-5250**

Date Issued: 06/30/20 0819 ET

FINAL REPORT

This document contains private and confidential health information protected by state and federal law.
If you have received this document in error, please call 800-631-5250

© 1995-2020 Laboratory Corporation of America® Holdings
All Rights Reserved - Enterprise Report Version: 1.00